These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34925237)

  • 1. Current and Potential Therapies Targeting Inflammation in NASH.
    Albhaisi S; Noureddin M
    Front Endocrinol (Lausanne); 2021; 12():767314. PubMed ID: 34925237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triggering and resolution of inflammation in NASH.
    Schuster S; Cabrera D; Arrese M; Feldstein AE
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice.
    Itoh M; Suganami T; Ogawa Y
    Endocr J; 2021 Jul; 68(7):743-749. PubMed ID: 33967185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
    Sunny NE; Bril F; Cusi K
    Trends Endocrinol Metab; 2017 Apr; 28(4):250-260. PubMed ID: 27986466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
    Tariq Z; Green CJ; Hodson L
    Liver Int; 2014 Aug; 34(7):e180-90. PubMed ID: 24621397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
    Kitade H; Chen G; Ni Y; Ota T
    Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.
    Mendez-Sanchez N; Cruz-Ramon VC; Ramirez-Perez OL; Hwang JP; Barranco-Fragoso B; Cordova-Gallardo J
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of nonalcoholic steatohepatitis.
    Liu W; Baker RD; Bhatia T; Zhu L; Baker SS
    Cell Mol Life Sci; 2016 May; 73(10):1969-87. PubMed ID: 26894897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic psychosocial stress on nonalcoholic steatohepatitis in mice.
    Czech B; Neumann ID; Müller M; Reber SO; Hellerbrand C
    Int J Clin Exp Pathol; 2013; 6(8):1585-93. PubMed ID: 23923077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic inflammatory responses in liver fibrosis.
    Hammerich L; Tacke F
    Nat Rev Gastroenterol Hepatol; 2023 Oct; 20(10):633-646. PubMed ID: 37400694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.